NHS Digital Data Release Register - reformatted

Public Health England (phe)

Project 1 — DARS-NIC-147794-JDPT1

Opt outs honoured: N

Sensitive: Sensitive, and Non Sensitive

When: 2016/04 (or before) — 2016/11.

Repeats: Ongoing

Legal basis: Other-NHS Regulations (3)

Categories: Identifiable

Datasets:

  • MRIS - Cause of Death Report
  • MRIS - Cohort Event Notification Report

Objectives:

Survival analysis of a cohort of Clostridium difficile infected and non- infected patients admitted to Addenbrooke’s Hospital between 2005 and 2007 To determine if Clostridium difficile (C. difficile) infection is associated with excess all cause mortality.


Project 2 — DARS-NIC-148119-WLQ4M

Opt outs honoured: Y, N

Sensitive: Non Sensitive, and Sensitive

When: 2016/04 (or before) — 2018/05.

Repeats: Ongoing

Legal basis: Other-NHS Regulations (3), Informed Patient consent to permit the receipt, processing and release of data by the HSCIC, Health and Social Care Act 2012, Section 42(4) of the Statistics and Registration Service Act (2007) as amended by section 287 of the Health and Social Care Act (2012)

Categories: Identifiable

Datasets:

  • MRIS - Cohort Event Notification Report
  • MRIS - Cause of Death Report
  • MRIS - Flagging Current Status Report
  • MRIS - Scottish NHS / Registration

Objectives:

Enhanced surveillance of individuals identified as at increased risk of vCJD/CJD in the UK due to iatrogenic exposures or other indicators of increased risk. This is a long term follow up study of people who have been placed at additional risk of contracting CJD. The aim of this work is to ascertain any CJD-related deaths amongst individuals identified by actions recommended by the CJD Incidents Panel as at increased risk of CJD. This information is critical to: a) improve assessment of the risks experienced by these individuals, and others in similar circumstances, b) inform and evaluate public health measures relating to these individuals; c) investigate factors associated with transmission, disease and survival in these individuals.


Project 3 — DARS-NIC-148161-XXPS5

Opt outs honoured: Y

Sensitive: Sensitive

When: 2016/04 (or before) — 2016/11.

Repeats: Ongoing

Legal basis: Section 251 approval is in place for the flow of identifiable data

Categories: Identifiable

Datasets:

  • MRIS - Cohort Event Notification Report
  • MRIS - Cause of Death Report
  • MRIS - Scottish NHS / Registration

Objectives:

The data supplied to the HPA CRCE Epidemiology Section will be used only for the approved Medical Research project - MR185 - UK Participants in the UK Atmospheric Nuclear Weapons Test (NWTPS)


Project 4 — DARS-NIC-148219-ZHB4Z

Opt outs honoured: Y, N

Sensitive: Sensitive

When: 2016/04 (or before) — 2016/11.

Repeats: Ongoing

Legal basis: Section 251 approval is in place for the flow of identifiable data

Categories: Identifiable

Datasets:

  • MRIS - Cohort Event Notification Report
  • MRIS - Cause of Death Report
  • MRIS - Scottish NHS / Registration
  • MRIS - Members and Postings Report

Objectives:

The data supplied to HPA CRCE Epidemiology Section will be used only for the approved medical research - MR47 National Registry for Radiation Workers


Project 5 — DARS-NIC-148465-PJQ4L

Opt outs honoured: Y

Sensitive: Sensitive

When: 2016/04 (or before) — 2016/08.

Repeats: Ongoing

Legal basis: Section 42(4) of the Statistics and Registration Service Act (2007) as amended by section 287 of the Health and Social Care Act (2012)

Categories: Identifiable

Datasets:

  • MRIS - Cohort Event Notification Report
  • MRIS - Cause of Death Report

Objectives:

To describe the current biochemical, histological and clinically apparent liver disturbance in cases of HCV infection, and to relate current status to the interval since presumed infection and other potential prognostic factors.


Project 6 — DARS-NIC-148473-G85HC

Opt outs honoured: N

Sensitive: Sensitive

When: 2016/04 (or before) — 2018/05.

Repeats: Ongoing

Legal basis: Informed Patient consent to permit the receipt, processing and release of data by the HSCIC, Other-NHS Regulations (3)

Categories: Identifiable

Datasets:

  • MRIS - Cohort Event Notification Report
  • MRIS - Cause of Death Report
  • MRIS - Flagging Current Status Report

Objectives:

To describe the clinical state at diagnosis and long-term outcome of HTLV infected individuals, 2). To investigate factors associated with transmission, disease an survival in HTLV infected individuals. Uninfected recipients (of donated blood) identified in the 'lookback' will provide a comparative group.


Project 7 — DARS-NIC-343380-H5Q9K

Opt outs honoured: Y, N

Sensitive: Sensitive, and Non Sensitive

When: 2017/09 — 2018/05.

Repeats: Ongoing

Legal basis: Section 251 approval is in place for the flow of identifiable data, Health and Social Care Act 2012, Section 42(4) of the Statistics and Registration Service Act (2007) as amended by section 287 of the Health and Social Care Act (2012)

Categories: Identifiable, Anonymised - ICO code compliant

Datasets:

  • Hospital Episode Statistics Accident and Emergency
  • Hospital Episode Statistics Admitted Patient Care
  • Hospital Episode Statistics Critical Care
  • Hospital Episode Statistics Outpatients
  • Standard Monthly Extract : SUS PbR A&E
  • Standard Monthly Extract : SUS PbR APC Episodes
  • Standard Monthly Extract : SUS PbR APC Spells
  • Standard Monthly Extract : SUS PbR OP
  • Diagnostic Imaging Dataset
  • Mental Health Services Data Set
  • National Child Measurement Programme (NCMP)
  • Sexual and Reproductive Health Activity Data (SRHAD)
  • Cancer Registration Data
  • Bridge file: Hospital Episode Statistics to Mortality Data from the Office of National Statistics
  • Primary Care Mortality Database
  • ONS Births
  • Vital Statistics Service

Processing:

The patient identifiable DIDS data provided by NHSD is held by PHE in the secure National Cancer Register system. Access to the identifiable data is limited to named PHE staff who are responsible for ensuring the completeness of the cancer registration records and the accuracy of the linkage to the DIDS data. Some of the analysis of the linked data is undertaken using identifiable data but the bulk is carried out using a version of the data that has had direct patient identifiers removed and replaced with pseudonyms. The analysis of the DIDS data is undertaken for the purposes described in this table. The DIDS data is not used for any purpose other than to analyse the treatment of patients with cancer. While the DIDS data is identifiable, the 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE cancer register uses of DIDS. The patient identifiable HES data provided by NHSD is held by PHE in the secure National Cancer Register system. Access to the identifiable data is limited to named PHE staff who are responsible for ensuring the completeness of the cancer registration records and the accuracy of the linkage of the HES data. Some of the analysis of the linked data is undertaken using identifiable data but the bulk is carried out using a version of the data that has had direct patient identifiers removed and replaced with pseudonyms. The analysis of the HES data is undertaken for the purposes described in this table. While the HES data is identifiable, the 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE cancer register uses of HES. All the data fields held by PHE in the cancer register are described in the Cancer Outcomes and Services Data set (COSD), which has been approved by the Standardisation Committee for Care Information based in NHS Digital (content.digital.nhs.uk/isce/publication/SCCI1521). The patient identifiable HES data provided by NHSD is held by PHE in a secure data server. Access to the data is limited to named staff in the PHE National Infection Service who are only allowed to use the data for the purposes described in this table. The information systems holding the linked data on antimicrobial resistance and healthcare associated infections, infectious disease control, respiratory diseases, and vaccine safety and effectiveness are all held and managed separately. While the HES data is identifiable, the 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the health protection uses of HES by PHE described here. The patient identifiable HES data provided by NHSD is held by PHE in the secure CARDS register system. Access to the identifiable data is limited to named PHE staff who are responsible for ensuring the completeness of the CARDS registration records and the accuracy of the linkage of the HES data. Some of the analysis of the linked data is undertaken using identifiable data but the bulk is carried out using a version of the data that has had direct patient identifiers removed and replaced with pseudonyms. The analysis of the HES data is undertaken for the purposes described in this table. While the HES data is identifiable, the 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE CARDS register uses of HES. The patient identifiable SUS data provided by NHSD is held by PHE in the secure National Cancer Register system. Access to the identifiable data is limited to named PHE staff who are responsible for ensuring the completeness of the cancer registration records and the accuracy of the linkage of the SUS data. Some of the analysis of the linked data is undertaken using identifiable data but the bulk is carried out using a version of the data that has had direct patient identifiers removed and replaced with pseudonyms. The analysis of the SUS data is undertaken for the purposes described in this table. While the SUS data is identifiable, the 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE cancer register use of SUS. The anonymised HES data provided by NHSD is held by PHE in a secure data server. Access to the data is limited to named PHE staff who are only allowed to use the data for the purposes described in this table. The 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE uses of HES. The HES data is anonymised so cannot and will not be directly linked by PHE to any other data, but it is analysed alongside other related sources of information such as local area deprivation scores to assess whether there are differences in disease rates and inequalities in the provision of hospital treatment between groups in the population. PHE only provides aggregate statistics and data tables based on HES data to Local Authorities. Local Authority access to anonymised HES extracts of data for individual patients is managed directly by NHSD. The anonymised MHSDS data provided by NHSD is held by PHE in a secure data server. Access to the data is limited to named PHE staff who are only allowed to use the data for the purposes described in this table. The 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE uses of MHSDS. The MHSDS data is anonymised so cannot and will not be directly linked by PHE to any other data, but it is analysed alongside other related sources of information such as substance misuse data. The anonymised NCMP data provided by NHSD is held by PHE in a secure data server. Access to the data is limited to named PHE staff who are only allowed to use the data for the purposes described in this table. The 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE uses of NCMP. The NCMP data is anonymised so cannot and will not be directly linked by PHE to any other data, but it is analysed alongside other related sources of information such as the location of fast food outlets to see if there is any association between this and levels of childhood obesity. The anonymised SHRAD data provided by NHSD is held by PHE in a secure data server. Access to the data is limited to named PHE staff who are only allowed to use the data for the purposes described in this table. The 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE uses of SRHAD. The SRHAD data is anonymised so cannot and will not be directly linked by PHE to any other data but it is analysed alongside other related sources of information such as the Genitourinary Medicine Clinic Activity Dataset (GUMCAD) to monitor STI rates and the treatments received by patients from SRH clinics. The patient identifiable PCMD data provided by NHSD is held by PHE in a secure data server. Access to the data is limited to named staff who are only allowed to use the data for the purposes described in this table. While the PCMD data is identifiable, the 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the uses of PCMD by PHE described here. The PCMD data is not directly linked by PHE to any other data but it is analysed alongside other related sources of information such as local area deprivation scores to assess whether there are differences in death rates between groups in the population and between different geographic areas. PHE only provides aggregate statistics and data tables based on PCMD data to Local Authorities and CCGs. Most Local Authorities have direct access to PCMD, which is managed by NHSD. The patient identifiable Linked HES/ONS Mortality data provided by NHSD is held by PHE in a secure data server. Access to the data is limited to named staff in the PHE End of Life Care team who are only allowed to use the data for the purposes described in this table. While the Linked HES/ONS Mortality data is identifiable, the 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the uses of Linked HES/ONS Mortality by PHE described here. The Linked HES/ONS Mortality data is not directly linked by PHE to any other data. The anonymised HSE data provided by NHSD is held by PHE in a secure data server. Access to the data is limited to named PHE staff who are only allowed to use the data for the purposes described in this table. The 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE uses of HSE. The HSE data is anonymised so cannot and will not be directly linked by PHE to any other data. The anonymised PSS-SACE data provided by NHSD is held by PHE in a secure data server. Access to the data is limited to named PHE staff who are only allowed to use the data for the purposes described in this table. The 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE uses of PSS-SACE. The PSS-SACE data is anonymised so cannot and will not be directly linked by PHE to any other data. The anonymised RDD data provided by NHSD is held by PHE in a secure data server. Access to the data is limited to named PHE staff who are only allowed to use the data for the purposes described in this table. The 12 ‘limited access controls’ set out by the ICO for anonymised data and described in Appendix C of this Memorandum apply to all the PHE uses of RDD. The RDD data is anonymised so cannot and will not be directly linked by PHE to any other data. The patient identifiable data provided by PHE to NHSD is held on secure server with access controls restricting access only to authorised internal users. Access is provided to staff directly involved in providing data to approved customers via the NHSD Data Access Request Service and to support PHE in query resolution and the accurate identification of cancer patients. Where cancer registration data is linked to other NHSD data sets, this is only undertaken where this is required and justified for internal use or to support authorised access to the patient status and tracking service where a legal basis is in place. Identifiable and non-identifiable data items are stored in separate tables to allow access to be granted independently as required for user needs. Where required for internal analysis, this is undertaken where possible on the non-identifiable table, including where linked to other data sets via a common NHSD pseudonymisation key.

Objectives:

The DIDS data contains information on the diagnostic imaging tests, such as x-rays and MRI scans, carried out on cancer patients treated in NHS hospitals in England. The identifiable patient data provided by NHSD to PHE is linked to the records of patients with cancer held by PHE on the National Cancer Register (https://www.gov.uk/guidance/national-cancer-registration-and-analysis-service-ncras). PHE has Section 251 support to collect information on all cases of cancer diagnosed in NHS hospitals in England and to link this to other sources of information on the diagnosis (such as DIDS), treatment and outcomes of these patients. The intelligence generated by cancer registration is used to improve the early detection and treatment of cancer, both by supporting direct patient care (for example, through genetic counselling services) and informing the commissioning and provision of improved diagnostic and treatment services.PHE is only provided with DIDS data for patients on the cancer register. PHE provides NHSD with a file containing NHS Number and the date of birth of cancer patients, which is then used to extract the relevant records from the DIDS system. This linked data is used to produce a range of statistics and analyse trends in the incidence and prevalence of different cancers, and to understand how effective different treatments are in improving patient outcomes. The results of these analyses are published by PHE in a range of indicators, analytical tools and reports such as the CancerData website at www.cancerdata.nhs.uk. The findings derived from the cancer register data are also used to inform the development and monitor the effectiveness of national policies and initiatives such as the National Cancer Strategy Implementation Plan. The HES data contains information on the diagnosis and treatment of all patients admitted to or attending NHS hospitals in England. The identifiable patient data provided by NHSD to PHE is linked to the records of patients with cancer held by PHE in the National Cancer Register. PHE has Section 251 support to collect information on all cases of cancer diagnosed in NHS hospitals in England and to link this to other sources of information on the diagnosis, treatment (such as HES) and outcomes of these patients. The HES data linked to cancer registration records is used to produce a range of statistics and analyse trends in the incidence and prevalence of different cancers, and to understand how effective different treatments are in improving patient outcomes. The results of these analyses are published by PHE in a range of indicators, analytical tools and reports such as the CancerData website at www.cancerdata.nhs.uk. The findings derived from the cancer register data are also used to inform the development and monitor the effectiveness of national policies and initiatives such as the National Cancer Strategy Implementation Plan.The patient identifiable HES data provided by NHSD to PHE is linked to a number of collections of information on patients with infectious diseases to monitor, investigate and manage: a)     antimicrobial resistanceb)    healthcare associated infectionsc)     respiratory diseasesd)    vaccine safetye)     vaccine efficacy and cost effectiveness. PHE is responsible for providing the national infrastructure for health protection including: an integrated surveillance system; specialist services such as diagnostic and reference microbiology; investigation and management of outbreaks of infectious diseases; ensuring effective emergency preparedness, resilience and response for health emergencies, including work on antimicrobial resistance; and evaluating the effectiveness of immunisation programmes and providing vaccines. HES is linked to laboratory data on antimicrobial resistance and healthcare associated infections to analyse the length of time affected patients spend in hospital and what their outcomes are in order to improve the way these threats to public health are managed. It is linked to laboratory data on infectious respiratory diseases to analyse the effectiveness of the treatments provided to patients. It is also linked to vaccination records to identify any health issues associated with new and existing vaccines, and to assess the efficacy and cost effectiveness of vaccines in preventing disease. The findings derived from the linked HES data primarily are used to inform the development and assess the effectiveness of clinical guidelines to improve the control of infections, the management of antimicrobial resistance and the treatment of respiratory diseases. The findings are also used to produce a range of indicators and reports such as the healthcare associated infections data at https://www.gov.uk/government/collections/healthcare-associated-infections-hcai-guidance-data-and-analysis and the vaccination information at https://www.gov.uk/government/collections/vaccine-uptake.The patient identifiable HES data provided by NHSD to PHE is linked to the records of individuals with a congenital anomaly or rare disease (CARD) held by PHE in the National Congenital Anomaly and Rare Diseases Register (https://www.gov.uk/guidance/the-national-congenital-anomaly-and-rare-disease-registration-service-ncardrs). PHE has Section 251 support to collect information on cases of CARDs in England and to link this to other sources of information on the diagnosis, treatment (such as HES) and outcomes of these individuals. This linked data is used to understand more about the incidence and prevalence of different CARDs in England, and about the treatment and outcomes of these individuals. A CARDS annual report will be produced in 2017/18 and prevalence statistics and prenatal detection rates are submitted to the European Surveillance of Congenital Anomalies (EUROCAT) network (http://www.eurocat-network.eu/). The findings derived from the CARDs register data are also used to inform the development and monitor the effectiveness of national policies and initiatives such as the UK Strategy for Rare Diseases.SUS data is essentially an earlier, less ‘clean’ version of the HES data described above (for example, not all duplicate records have been removed) and contains information on the diagnosis and treatment of all patients admitted to or attending NHS hospitals in England. The identifiable patient data provided by NHSD to PHE is linked to the records of patients with cancer held by PHE in the National Cancer Register. Data is only provided by NHSD for patients with a cancer-related ICD-10 diagnosis code. This linked data is used for the specific purpose of producing a set of monthly-updated cancer outcomes metrics on the performance of the NHS in diagnosing and treating cancer patients as soon as possible, such as cancer stage at diagnosis and the percentage of cases diagnosed as an emergency. These metrics, as well as other statistics based on the analysis of data from the cancer register, are published at http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/cancer_outcome_metrics. The HES data contains information on the diagnosis and treatment of all patients admitted to or attending NHS hospitals in England. The anonymised data provided by NHSD to PHE is used to produce a range of statistics and analyse trends in the incidence and prevalence of a wide range of conditions such as heart disease and stroke, mental health and respiratory disease. The results of these analyses are published by PHE in a range of indicators, analytical tools and reports such as the Public Health Outcomes Framework at http://www.phoutcomes.info/. The findings derived from HES data are used to inform the development and monitor the effectiveness of national policies and initiatives aimed at protecting and improving public health and reducing health inequalities. The HES data is also analysed by PHE to produce statistics to help Local Authorities fulfil their statutory duty to improve the health of their local population, for example through the production of joint strategic needs assessments and local health and wellbeing strategies. The MHSDS contains information on the diagnosis and treatment of patients admitted to or attending NHS hospitals and treatment centres with mental health problems in England. The anonymised data provided by NHSD to PHE is used to produce a range of statistics and analyse trends in the incidence and prevalence of mental health problems such as dementia and depression and anxiety. The results of these analyses are published by PHE in a range of indicators, analytical tools and reports such as the Common Mental Health Disorders Profiling Tool at https://fingertips.phe.org.uk/profile-group/mental-health/profile/common-mental-disorders. The findings derived from MHSDS are also used by PHE to develop and assess the effectiveness of national policies aimed at improving the lives of people with mental health problems, and by Local Authorities to provide mental health services at a local level. The NCMP provides information on the height and weight of all children in reception (aged 4-5 years) and year 6 (aged 10-11 years) in schools in England. PHE is the sponsor on behalf of the Secretary of State of the national collection of NCMP data by NHSD from all Local Authorities. The anonymised data provided by NHSD to PHE is used to analyse variations and trends in the percentages of children who are underweight, normal weight, overweight and obese. The results of these analyses are published by PHE in a range of indicators, analytical tools and reports such as the local authority profiles at http://fingertips.phe.org.uk/profile/national-child-measurement-programme. PHE also use the data to provide statistics to schools on the percentage of children who are an unhealthy weight.The NCMP findings are used by PHE to develop national policies to increase the proportion of children who are normal weight, and by Local Authorities to provide services that support families to make healthy lifestyle changes. The SRHAD collects information on the contraception, sexually transmitted infections (STI) and reproductive health advice and care provided to patients attending sexual and reproductive health (SRH) services in England. PHE is the sponsor on behalf of the Secretary of State for the national collection of SRHAD data by NHSD from all SRH services. The anonymised data provided by NHSD to PHE is used to monitor the implementation of key national sexual health policy objectives such as: increasing access to all methods of contraception, including long acting reversible contraception and emergency contraception, and reducing inequalities in access to services; reducing teenage conceptions; and reducing unintended pregnancies. The results of these analyses are published by PHE in a range of indicators, analytical tools and reports such as the local authority sexual and reproductive health profiles at https://fingertips.phe.org.uk/profile/sexualhealth. The SRHAD findings are used by PHE to develop and monitor national policies for Sexual Health and HIV, and by Local Authorities to provide SRH services to improve sexual and reproductive health across England.


Project 8 — HDIS_Public Health England (PHE)

Opt outs honoured: N

Sensitive: Non Sensitive

When: 2016/04 (or before) — 2016/08.

Repeats: Ongoing

Legal basis: Health and Social Care Act 2012

Categories: Anonymised - ICO code compliant

Datasets:

  • Access to HES Data Interrogation system

Objectives:

The HES (Hospital Episode Statistics) Data Interrogation System (HDIS) allows users to securely access HES, interrogate the data, perform aggregations, statistical analysis, and produce a range of different outputs. Access to HDIS is only provided to organisations who work within the public sector with a specific interest in public health. There is a strict information governance applications process in place to protect and control how the data is managed.


Project 9 — NIC-154590-YG6QH

Opt outs honoured: N

Sensitive: Sensitive

When: 2017/09 — 2018/05.

Repeats: Ongoing

Legal basis: Health and Social Care Act 2012

Categories: Identifiable

Datasets:

  • Patient level data relating to Diabetic Retinopathy Eye Screening FOR DIRECT CARE

Objectives:

Objective for processing: The diabetic retinopathy screening program will use:• the demographic patient information transferred to invite people recently-diagnosed with diabetes for annual screening;• the relevant clinical information transferred about patients who attend clinic appointments so that appropriate patient care is provided to those patients;Processing activities:For each monthly cohort, all patients with diabetes codes (Diabetes Exclusions CST, Diabetes Resolved CST and Diabetes CST) will be identified by the HSCIC and only those who have 'Diabetes CST' as their latest code will then have demographic and clinical data extracted for them. The full list of all required demographic data will be extracted by the HSCIC alongside the latest diabetes code including the date and time of this record.The Data Provider Output (DPO) is the data that general practice system suppliers extract from general practice clinical systems and submit to the HSCIC. The DPO is based on the data extraction specification (referred to as the ‘Extraction Requirement’) that the HSCIC circulates to general practice system suppliers.There will be a small amount of data transformation performed on the DPO. The HSCIC will use the General Practice Extraction Tool - Query (GPET-Q) system to collate the general practices’ DPO data into a file and then send the resulting file to the HSCIC Data Management Environment (DME). This is the 'Full Cohort' extract.Two data attributes (NHS Number and Registered Practice Id) will be copied from the file into a further file which will be stored in the HSCIC DME. This is the 'Missing Patients' extract. It identifies the patients with diabetes extracted in the previous month’s extraction run, and the practices at which those patients were registered. Each month the HSCIC will replace the file with a new file of patient identifiers. Without that information it would be possible to send out confidential invitation letters inappropriately (e.g. to a person who has died, to the wrong address), potentially “lose” people in need of diabetic retinopathy services, and/or spend time and money investigating the "missing patients".The 'Missing Patients' and 'Full Cohort' extracts are the two data extracts that form the output files. The HSCIC processes and places the output files in a secure repository for Quicksilva (data processor for the 72 NHS diabetic retinopathy screening programmes) to download. The HSCIC retains the list of NHS numbers and GP practices until the next extract for the purpose of identifying the patients missing between months. This list will be destroyed once approved data about the missing patients has been extracted and sent to the 72 NHS diabetic retinopathy screening programmes. The data received will be stored within the central database of patient records maintained by the NHS diabetic retinopathy screening programme and used for the purposes described above.The screening database of patient records is maintained in data centres in Harrogate & London which are provided by Redcentric PLC (Redcentric PLC is certified in ISO27001, ISO9001 and NHS IG Toolkit 12 (commercial third party)). Quicksilva manage and operate the screening database and process the data to the requirements of the Public Health England. After processing activities, the data is sent using a N3 host to the 72 NHS diabetic retinopathy screening programmes dedicated systems located within secure care provider network environments (e.g. NHS trusts) and also sent to data reconciliation tools which updates patient demographic data with local clinical system data.In order that the right people get access to the right data, the screening database includes:• a mapping of the patient’s general practice to a local screening program;• role based access controls that limit what patient data can be accessed depending on a specific role;• and audit trails to detect any unauthorised and/or excessive access.In addition to the data provided to PHE, two data attributes (NHS Number and Practice) will be stored in the HSCIC DME to be used in future extractions Specific outputs expected, including target date:The data will be used on an ongoing basis within patient records maintained by the NHS diabetic retinopathy screening programme to invite patients for screening, and to enable clinicians to provide appropriate clinical care. This database will be updated monthly.Expected measurable benefits to health and/or social care including target date:See “03_GP2DRS - Benefits Plan - August 2013 (NIC-154590-YG6QH)”


Project 10 — PHECancerReg

Opt outs honoured: N

Sensitive: Sensitive

When: 2016/09 — 2018/05.

Repeats: Ongoing

Legal basis: Informed Patient consent to permit the receipt, processing and release of data by the HSCIC

Categories: Identifiable

Datasets:

  • Cancer Registry linked to Diagnostic Imaging Dataset

Objectives:

To extend the information available for a cancer pathway, by linking data to Cancer Registry information